Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1638 1644 1675
This examiner grants 45% of resolved cases
Amy E Juedes is a USPTO patent examiner in Tech Center 1600 and Art Unit 1638. The examiner has 921 resolved cases, which results in an allowance rate of 44.8%. This percentage indicates the frequency of granted patents among the resolutions. The median days to allowance for these cases is 1386, providing a benchmark for the timeline of successful prosecution in this unit.
The data shows an interview lift of 41.7%. This figure indicates that applications involving an interview have a higher probability of allowance than those without one. With 921 resolved cases, the examiner has a history of resolutions in Tech Center 1600. Practitioners can use the 1386-day median to manage expectations regarding the duration of the patent acquisition process.
In Art Unit 1638, the examiner's 44.8% allowance rate and 41.7% interview lift are metrics for strategy. The median pendency is a figure that describes the time required to reach an allowance. These data points from the resolved cases offer an overview of the examiner's performance. Applicants should consider the 41.7% lift when deciding whether to request an interview.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18037514 | BOVINE ANTIBODY VARIANTS | Non-Final OA | Zoetis Services LLC |
| 18587251 | METHODS OF TREATING TAU PATHOLOGIES | Non-Final OA | Genentech, Inc. |
| 18021687 | B-CELL BASED IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Final Rejection | Northwestern University |
| 18281471 | ENGINEERED IMMUNE CELLS AND USES THEREOF | Non-Final OA | The Johns Hopkins University |
| 18559146 | INHIBITORY CHIMERIC ANTIGEN RECEPTOR PREVENTS ON-TARGET OFF-TUMOR EFFECTS OF ADOPTIVE CELL THERAPY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18263658 | IMPROVED T-CELLS FOR CANCER THERAPY USING AMINO ACID STARVATION PATHWAYS | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18625699 | METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18708163 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | Non-Final OA | Sloan-Kettering Institute for Cancer Research |
| 18550914 | METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS | Non-Final OA | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH |
| 14437902 | METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | Final Rejection | City of Hope |
| 17276959 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES | Final Rejection | The United States of America,as represented by the Secretary,Department of Health and Human Services |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy